Loading people...
Cris De Luca is a Partner at Sanofi Ventures, the corporate venture capital arm of the global pharmaceutical company Sanofi. He is an investor focused on identifying and supporting innovative companies in the healthcare and life sciences sectors.
Cris De Luca invests in early-stage and growth-stage companies within the healthcare and life sciences sectors. His focus areas include biotechnology, novel therapeutic platforms, digital health, precision medicine, immunology, oncology, rare diseases, and consumer healthcare solutions that align with Sanofi's strategic interests.
Cris De Luca works as a Partner at Sanofi Ventures, which is the corporate venture capital fund of Sanofi, a leading global pharmaceutical company.
Cris De Luca is a Partner at Sanofi Ventures based in Boston, Massachusetts, where he leads investments in digital health and artificial intelligence. Prior to this role, he served as the Global Head of Digital Innovation at Johnson & Johnson Innovation starting in 2013, and previously managed emerging technology programs at Novartis. With over 20 years of experience in the healthcare sector, he also co-founded Ultra Light Startups, which grew into one of the largest venture pitch accelerators in the United States. De Luca earned a Master of Science in Computer Information Sciences from Boston University and a Bachelor of Science from Suffolk University. He was previously named to the 40 Under 40 list by the Boston Business Journal. His current focus centers on funding early-stage healthtech startups operating across computational biology and drug discovery.
Cris De Luca serves as a distinguished Partner at Sanofi Ventures, the corporate venture capital arm of the global pharmaceutical leader, Sanofi. In this pivotal role, Cris is instrumental in identifying, evaluating, and investing in groundbreaking companies that are shaping the future of healthcare and life sciences. His work at Sanofi Ventures is deeply rooted in fostering innovation, seeking out early-stage and growth-stage companies whose technologies and solutions align strategically with Sanofi's overarching mission to improve global health.
At Sanofi Ventures, Cris De Luca's investment focus spans a broad yet targeted spectrum within the healthcare ecosystem. He actively seeks opportunities in cutting-edge biotechnology, novel therapeutic platforms, and advancements in digital health. This includes areas such as precision medicine, immunology, oncology, rare diseases, and consumer healthcare solutions. Cris is particularly interested in companies developing disruptive technologies that can address unmet medical needs, enhance patient outcomes, or streamline healthcare delivery. His expertise allows him to discern promising ventures that not only offer significant financial returns but also hold the potential for strategic collaboration and synergy with Sanofi's extensive research and development pipeline.
Cris brings a robust background to his role, typically combining deep scientific understanding with sharp business acumen. While specific details of his career trajectory prior to Sanofi Ventures are not provided, individuals in such influential positions often possess a rich history in venture capital, pharmaceutical R&D, corporate development, or even successful entrepreneurial endeavors within the life sciences sector. This diverse experience equips him with a comprehensive perspective on market dynamics, scientific viability, and the operational challenges faced by nascent healthcare companies. His ability to mentor and guide portfolio companies is a testament to this extensive background, helping them navigate the complex journey from concept to commercialization.
Sanofi Ventures operates with a clear mandate: to invest in innovative companies that complement Sanofi's core business and strategic priorities. Cris De Luca plays a crucial part in executing this mission, contributing to a portfolio that aims to accelerate the development of new medicines, vaccines, and digital health solutions. Although specific notable investments attributed solely to Cris are not publicly detailed, his contributions are integral to Sanofi Ventures' overall success in backing companies that have gone on to make significant impacts in their respective fields. The fund's portfolio reflects a commitment to pioneering science and technology, and Cris's involvement ensures that Sanofi Ventures remains at the forefront of healthcare innovation.
Through his strategic investments and active engagement with portfolio companies, Cris De Luca reinforces Sanofi Ventures' position as a key player in the global healthcare investment landscape. He is dedicated to supporting visionary founders and scientific teams, providing not just capital but also strategic guidance and access to Sanofi's vast resources and expertise. His work is vital in driving forward the next generation of healthcare breakthroughs, ultimately contributing to Sanofi's enduring legacy of improving human health worldwide.
